Navigation Links
AbbVie Issues Inaugural Full-Year Outlook for 2013
Date:1/30/2013

and the advancement of key development programs, including the start of Phase III studies for our interferon-free Hepatitis C (HCV) combination and elagolix.

AbbVie expects long-term growth will be fueled by a compelling pipeline of therapies in development to address medical conditions with high unmet need.  The company is focused on advancing a number of Phase III programs, including: an interferon-free oral combination for HCV; daclizumab for relapsing remitting multiple sclerosis (in partnership with Biogen); elagolix for endometriosis; elotuzumab for multiple myeloma (in partnership with Bristol Myers Squibb); and several new indications for HUMIRA.

In 2013, the company expects to initiate several Phase III programs including atrasentan for diabetic kidney disease and ABT-199 in chronic lymphocytic leukemia (CLL).  Additionally, AbbVie is planning Phase IIB starts for: elagolix in uterine fibroids; our partnered JAK1 inhibitor (GLPG0634) for rheumatoid arthritis (RA); BT-061 for RA; and ABT-719 for acute kidney injury associated with major cardiac and other surgeries.  Finally, in 2013, the company intends to present data from a number of key development programs, including our rapidly advancing HCV program, oncology, renal disease, immunology and Alzheimer's disease.

Management to Discuss Company Performance and Outlook on Investor Call TodayAbbVie will host an investor conference call today at 8 a.m. Central time to discuss our fourth-quarter and full-year 2012 highlights and 2013 outlook. Participating on the call will be Rick Gonzalez , chairman and chief executive officer; Bill Chase , executive vice president and chief financial officer; Laura Schumacher , executive vice president of business development, external affairs and general counsel; John Leonard , senior vice president and chief scientific o
'/>"/>

SOURCE AbbVie
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. AbbVie Named to S&P 500 Dividend Aristocrat Index
2. Emmaus Life Sciences Issues Statement in Response to Announcement by AFH Holding & Advisory
3. Qualitest Issues Voluntary, Nationwide Recall of 101 Lots of Hydrocodone Bitartrate and Acetaminophen Tablets, USP 10 mg/500 mg Due to the Potential for Oversized Tablets
4. Fero Industries, Inc. Issues Corporate Update
5. CSL Behring Parent Company, CSL Limited, Issues Fourth Corporate Responsibility Report
6. Ranbaxy Issues Voluntary Nationwide Recall of 41 lots of Atorvastatin Calcium Tablets 10 mg, 20 mg and 40 mg Due to Potential Presence of Foreign Substance
7. Emmaus CEO Yutaka Niihara, M.D., Issues Statement In Connection with Status of Companys Phase III FDA Sickle Cell Treatment Trials
8. Zi Xiu Tang Success, LLC Issues Voluntary Nationwide Recall of Classic Zi Xiu Tang Bee Pollen Capsules and Ultimate Formula Capsules due to Undeclared Sibutramine
9. CORRECTION: Star Scientific Issues Statement Correcting the Underreporting of the "Flint" CRP Human Study Results
10. Qualitest Issues Voluntary, Nationwide Recall for One Lot of Hydrocodone Bitartrate and Acetaminophen Tablets, USP 10 mg/500 mg Due to the Potential for Oversized Tablets
11. Sun Pharmaceutical Industries, Inc. Issues Nationwide Voluntary Recall of One Lot of Nimodipine Capsules due to Crystallization of the Fill Material
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... May 21, 2015  Cardica, Inc. (Nasdaq: CRDC ) ... Greg Watson , the company,s vice president of operations, was ... common stock, at a per share exercise price of $0.43, ... option was granted pursuant to Cardica, Inc.,s Inducement Plan, which ... 2015 under Rule 5653(c)(4) of the Nasdaq Global Market for ...
(Date:5/21/2015)... -- Heidrick & Struggles (Nasdaq: HSII ), the premier ... and culture shaping worldwide, strengthens its ... the addition of Tim Dietlin to the ... Dietlin has extensive life sciences and professional services ... and Commercial functions to increase productivity, drive transformational change, ...
(Date:5/21/2015)... Fla. , May 21, 2015 Bankers Healthcare ... is publishing a new blog series from medical writer ... The series will analyze the decision making process, ... and provide insight as to how healthcare practitioners can make ... the series was published May 7, 2015: " Being More ...
Breaking Medicine Technology:Cardica Announces New Employment Inducement Grant 2Heidrick Increases Healthcare and Life Sciences Expertise 2Medical Writer Dr. Pat Bass Publishes A New Series On The Bankers Healthcare Group BHG360 Blog 2Medical Writer Dr. Pat Bass Publishes A New Series On The Bankers Healthcare Group BHG360 Blog 3
... R.I., Nov. 2, 2010 CVS Caremark reiterated the ... (FDA) implement regulations necessary to approve biogeneric drugs under ... of Specialty Pharmacy Operations, Scott Reid, testified before the ... development of an approval pathway for biosimilar and interchangeable ...
... cancer treatments across India will become more widely available ... (NYSE: VAR ) medical linear accelerators by ... groups. Three TrueBeam™ STx systems and a UNIQUE™ accelerator ... Chennai, Mumbai and Hyderabad in 2011. "This ...
Cached Medicine Technology:CVS Caremark Reiterates Support for FDA Implementation of Approval Pathway for Biogeneric Drugs 2Varian Medical Systems to Supply Four Advanced Radiotherapy Treatment Machines to Global Hospitals in India 2Varian Medical Systems to Supply Four Advanced Radiotherapy Treatment Machines to Global Hospitals in India 3
(Date:5/22/2015)... Co founders Greenlee and James Chapko, DDS have launched ... immediately deliver fully integrated dental implant services to their patients. ... surgeon. , The Center, whose name is ImplantWide, ... placing dental implants. These 6 roadblocks can discourage any ... placement of dental implants into his or her practice. ...
(Date:5/22/2015)... 22, 2015 Puritan Medical Products, ... the medical, diagnostic, environmental, and forensics industries celebrates ... products in the US. At a time when ... the US, Puritan remains committed to designing and ... Guilford, Maine facility. , Since 1919, Puritan has ...
(Date:5/22/2015)... WI (PRWEB) May 22, 2015 ... honor to be recognized for providing the highest quality ... foundation of health care decision-making,” said Javon R. Bea, ... demonstrates the commitment of our employee/partners to care for ... patients.” , Hospitals do not apply for this award, ...
(Date:5/21/2015)... York, New York (PRWEB) May 21, 2015 ... distributor of patented products, launches the Troll Motor Guide, ... convenient way of boating. , "The recreational boating industry ... Scott J. Cooper, CEO and Creative Director of ... water in record numbers and predicts continued steady growth ...
(Date:5/21/2015)... 2015 Absolute Exhibits, a trade ... state-of-the-art website that is filled with essential exhibiting tools ... information. With its original and inventive design ideas, it ... website shows hundred of pictures of client- owned or ... is not an exhibit rendering site, rather real-time pictures ...
Breaking Medicine News(10 mins):Health News:First of Its Kind Dental Implant Training and Surgicenter to Open in June 2Health News:Maine Swab Company Celebrates 96 Years of American-made Products 2Health News:Mercy Hospital and Trauma Center Receives Women’s Choice Award for Emergency Care - Mercy Health System Javon Bea 2Health News:Great Ways To Celebrate On Memorial Day Weekend- Starting With World Patent Marketing's New Boat Patent 2Health News:Great Ways To Celebrate On Memorial Day Weekend- Starting With World Patent Marketing's New Boat Patent 3Health News:New Convention and City Travel Guides Within the Absolute Exhibits’ Website 2
... (Feb. 2, 2012) Different kinds of lung cancer ... diseases. According to a University of Colorado Cancer Center ... of the American Cancer Society, different subgroups of non-small ... in the body. The study looked at ...
... By Kathleen Doheny HealthDay Reporter , THURSDAY, Feb. ... tend to eat as much or as little as their dining ... finds that women who share a meal with women they have ... at the same time. "The aim of our study was ...
... of a multicenter study coordinated by researchers at ... investigational urine-based biomarkers are associated with prostate cancers ... life-threatening among men who take a "watchful waiting," ... these markers may lead to the development of ...
... HealthDay Reporter , THURSDAY, Feb. 2 (HealthDay News) -- The ... part in determining your stroke risk, new research suggests. ... for us, in terms of skin cancer for example," noted ... the University of Alabama at Birmingham. "But this examination of ...
... A new study published in the journal Pharmacoepidemiology ... prescription statins directly to consumers are widespread, and that ... public contain very poor levels of information relevant to ... led by Professor David Brown, School of Pharmacy and ...
... High levels of a personality trait called harm avoidance -- ... associated with a higher stroke risk, a new study indicates. ... rated on the 35-item Harm Avoidance Scale. During 3-1/2 years ... percent underwent a brain autopsy. People who scored high ...
Cached Medicine News:Health News:New research confirms need for lung cancer testing 2Health News:If Your Dining Partner Overeats, So May You 2Health News:If Your Dining Partner Overeats, So May You 3Health News:Investigational urine test can predict high-risk prostate cancer in men who chose 'watchful waiting' 2Health News:Lack of Sunlight May Raise Stroke Risk 2
... the easiest test to use on the market. ... no hands-on time. Critical care instructions can be ... the pediatrician's office. Valuable information can be obtained ... Now the focus can be on the results ...
The QuickScreen Pro Multi Drug Screening Test is a rapid, self-timing, qualitative immunoassay for,the detection of drugs of abuse in urine....
... qualitative immunoassays for detecting elevated levels of Luteinizing ... and results are easy to interpret. If ... the control band, then ovulation will probably occur ... test band does not appear or is lighter ...
Detect LH surge for predicting ovulation, Able to detect as low as 40 mIU/mL LH or 30 mIU/mL LH, Simple, easy and accurate, Built-in control system...
Medicine Products: